Alto Neuroscience filings document the regulatory record of a clinical-stage biopharmaceutical issuer developing precision medicines for neuropsychiatric disorders. Form 8-K reports cover operating and financial results, clinical updates for programs such as ALTO-101 and ALTO-207, and material definitive agreements tied to private placements of common stock and pre-funded warrants.
Proxy materials describe annual meeting matters, including director elections, auditor ratification and proposed amendments to the company’s equity incentive and employee stock purchase plans. The filings also identify ANRO common stock registered on the New York Stock Exchange and the company’s emerging growth company status.
Alto Neuroscience, Inc. Chief Financial Officer & CBO Nicholas Conrad Smith reported a Form 4 transaction involving company common stock. On March 1, 2026, 2,806 shares were withheld at $19.69 per share to cover taxes upon vesting of restricted stock units, rather than through an open market trade. After this tax-withholding disposition, he directly held 24,060 common shares.
Alto Neuroscience, Inc. — Armistice Capital, LLC and Steven Boyd reported beneficial ownership of 1,536,000 shares, representing 4.94% of common stock as of 12/31/2025.
The filing states Armistice Capital exercises shared voting and dispositive power over the 1,536,000 shares held by Armistice Capital Master Fund Ltd., and that the Master Fund has the right to receive dividends or sale proceeds. The Master Fund disclaims beneficial ownership by virtue of its Investment Management Agreement; Mr. Boyd, as managing member, may be deemed to beneficially own the securities.
Armistice Capital, LLC and Steven Boyd filed an amendment to their Schedule 13G reporting beneficial ownership of 1,536,000 shares of Alto Neuroscience common stock, representing 4.94% of the class. The filing states Armistice Capital, as investment manager to Armistice Capital Master Fund Ltd., exercises shared voting and dispositive power over those shares, and Mr. Boyd, as managing member, may be deemed to beneficially own them. The Master Fund disclaims beneficial ownership by virtue of its Investment Management Agreement with Armistice Capital.
K2 HealthVentures Equity Trust LLC, together with Parag Shah and Anup Arora, reports beneficial ownership of 788,995 shares of Alto Neuroscience, Inc. common stock, or about 2.4% of the class as of December 31, 2025.
This stake includes 30,000 shares held directly, 170,464 shares underlying warrants, and 588,531 shares issuable upon conversion of Alto’s outstanding debt owed to K2HV Equity under a loan and security agreement, as amended. The filers state the securities were not acquired to change or influence control of Alto Neuroscience.
Alto Neuroscience, Inc. received an updated ownership report showing that funds affiliated with Point72 and Steven A. Cohen beneficially owned 2,824,275 shares of its common stock, representing 8.9% of the company as of December 31, 2025. This total includes 549,543 shares issuable upon exercise of warrants.
The stake is held through several Delaware entities, including Point72 Asset Management, Point72 Capital Advisors, Point72 Biotech Private Investments, Differentiated Ventures, and 72 Investment Holdings, with Point72 Associates entitled to dividends and sale proceeds on more than 5% of the stock. The reporting persons certify the securities were not acquired to change or influence control of Alto Neuroscience.
Commodore Capital and related filers report a significant passive stake in Alto Neuroscience, Inc. They filed an amended Schedule 13G/A showing beneficial ownership of 3,245,628 shares of common stock, representing 9.9% of the class as of December 31, 2025.
The position consists of 1,823,196 Alto Neuroscience shares and 1,422,432 additional shares that each filer may acquire through exercising a pre-funded warrant, which is subject to a 9.99% beneficial ownership limitation. The calculation uses 31,066,335 shares outstanding as of November 7, 2025 plus the warrant shares. The filers certify the securities are not held to change or influence control of Alto Neuroscience.
Vestal Point Capital reports beneficial ownership of 2,485,000 shares of Alto Neuroscience common stock, representing 8% of the class. The shares are held through the Vestal Point fund and a managed account, with voting and dispositive power shared between Vestal Point Capital and Ryan Wilder.
The ownership percentage is based on 31,066,335 shares of Alto Neuroscience common stock outstanding as of November 7, 2025. The securities are certified as being acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of Alto Neuroscience.
Perceptive Advisors and affiliates report a 9.99% stake in Alto Neuroscience, Inc. They beneficially own 3,249,934 shares of common stock, including shares issuable under pre-funded warrants, based on 31,066,335 Alto shares outstanding as of November 7, 2025.
The Master Fund directly holds 1,784,393 Alto common shares and 2,536,354 pre-funded warrants exercisable at $0.0001 per share, subject to a 9.99% beneficial ownership cap. Perceptive Advisors acts as investment manager to the Master Fund, and Joseph Edelman is the managing member of Perceptive Advisors.
The reporting persons certify the securities were not acquired and are not held to change or influence control of Alto Neuroscience, other than activities solely connected with a nomination under Rule 14a-11.
Alto Neuroscience reported that President and CEO Etkin Amit received an employee stock option grant on February 11, 2026. The option covers 306,000 shares of common stock at an exercise price of $16.71 per share and expires on February 10, 2036.
According to the vesting terms, 25% of the shares vest on February 11, 2027, with the remaining shares vesting in equal monthly installments over the following three years, contingent on his continued service. After this award, Amit directly holds options for 306,000 shares.
Alto Neuroscience Chief Medical Officer Adam Savitz received a grant of 124,000 employee stock options on February 11, 2026. The options have an exercise price of $16.71 per share and expire on February 10, 2036. They relate to Alto Neuroscience common stock.
According to the vesting terms, 25% of the shares underlying the option will vest on February 11, 2027. The remaining shares will then vest in equal monthly installments over the following three years, provided Savitz continues in service through each vesting date. After this grant, he directly holds 124,000 derivative securities in the form of these options.